Overview

Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Gathering information about how young patients with ependymoma respond to standard combination chemotherapy and learning about the long-term effects of this treatment may help doctors plan better treatment. PURPOSE: This phase III trial is observing young patients with ependymoma undergoing standard combination chemotherapy.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Children's Cancer and Leukaemia Group
Treatments:
Carboplatin
Cyclophosphamide
Methotrexate
Vincristine
Criteria
DISEASE CHARACTERISTICS:

- Histologically confirmed WHO grade 3 anaplastic (malignant) ependymoma or WHO grade 2
ependymoma, including the following variants:

- Papillary

- Cellular

- Clear cell

- Tanycytic

- No myxopapillary ependymoma, subependymoma, or ependymoblastoma

- Meets 1 of the following criteria:

- Has undergone complete resection of the primary tumor (prior to starting
chemotherapy)

- Two or more surgical procedures to achieve complete resection allowed

- Metastatic disease at diagnosis (with or without complete resection of the
primary tumor)

- Unable to undergo complete resection of the primary tumor (with or without
metastatic disease)

- Patients with measurable residual disease (primary or metastatic disease) are eligible
provided they undergo treatment on clinical trial CCLG-CNS-2005-03 prior to entering
this study

- Has undergone surgical resection OR completed treatment on clinical trial
CCLG-CNS-2005-03 within the past 3 weeks

- Patients who are unable to tolerate chemotherapy or who do not receive treatment
according to the CCLG guidelines for ependymoma due to parental preference or
recommendation from the treating physician are eligible

PATIENT CHARACTERISTICS:

- Able to tolerate IV hydration

- No active infection

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics